Lv21
105 积分 2021-03-06 加入
Advancements and future trends of immunotherapy in light-chain amyloidosis
3小时前
已完结
Management of Cytokine Release Syndrome (CRS) and HLH
3小时前
已完结
Management of Cytokine Release Syndrome (CRS) and HLH
3小时前
已关闭
Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population
4小时前
求助中
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis
5小时前
已完结
Cardiac Amyloidosis: How Its Epidemiology is Changing
4天前
求助中
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment
5天前
已完结
BispecificCARTcelltherapytargetingBCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
6天前
已完结
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
6天前
已完结
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
6天前
已完结
皖公网安备34019202002308
